Atenolol

證據等級: L5

預測適應症: 9 個

Atenolol: From Hypertension/Angina to Posteroinferior Myocardial Infarction

One-Sentence Summary

Atenolol is a cardioselective β1-adrenergic blocker widely used for the treatment of hypertension, angina pectoris, and cardiac arrhythmias. The TxGNN model predicts it may be effective for posteroinferior myocardial infarction, with 0 clinical trials and 1 publication currently supporting this specific anatomical subtype, though β-blockers are well established in the broader myocardial infarction setting. Across all 9 predicted indications, the strongest evidence base exists for chronic pulmonary heart disease (1 clinical trial, 15 publications), though that indication carries significant mechanistic concerns.

Quick Overview

Item	Content
Original Indication	Hypertension, angina pectoris, cardiac arrhythmias (well-established β-blocker)
Predicted New Indication	Posteroinferior myocardial infarction
TxGNN Prediction Score	99.87%
Evidence Level	L4 (Preclinical / mechanism-level studies)
NL Market Status	Not found in evidence pack (Note: Atenolol is widely available in NL under multiple CBG-MEB authorizations — see section below)
Number of Authorizations	0 in current dataset (regulatory data gap)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Atenolol is a selective β1-adrenergic receptor antagonist. It works by competitively blocking β1-receptors predominantly located in the heart, thereby reducing heart rate, myocardial contractility, and myocardial oxygen demand. These properties are the basis of its longstanding use in hypertension, stable angina, and post-myocardial infarction (MI) secondary prevention. Atenolol does not possess intrinsic sympathomimetic activity (ISA), making it suitable for reducing sympathetic overdrive in acute coronary events.

Posteroinferior myocardial infarction is an anatomical subtype of MI affecting the posterior and inferior walls of the left ventricle, typically caused by occlusion of the right coronary artery or the left circumflex artery. β-blockers, including atenolol, are already part of standard MI secondary prevention protocols per ESC and AHA/ACC guidelines. The TxGNN model’s prediction essentially identifies that the existing pharmacological mechanism is fully applicable to this anatomical subtype — a logical extension given that β-blocker cardioprotection (reduction of infarct size, prevention of reinfarction, and reduction of sudden cardiac death) is not dependent on infarct location.

However, it is important to note that posteroinferior MI often involves the right ventricle and the cardiac conduction system (particularly the AV node), which means that β-blocker use requires additional caution. Bradycardia, AV block, and right ventricular dysfunction are specific risks in this patient population, and clinical monitoring should be more intensive than in anterior MI.

Clinical Trial Evidence

Currently no clinical trials specifically studying atenolol for posteroinferior myocardial infarction are registered.

Note: While no trials target this specific anatomical subtype, atenolol has been extensively studied in the broader MI context. The landmark ISIS-1 trial (1986) demonstrated a 15% reduction in vascular mortality with early IV atenolol in acute MI. The following trial from a related predicted indication (chronic pulmonary heart disease) provides indirect context:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03278509	Phase 4	Active, not recruiting	5,000	REDUCE-SWEDEHEART: Evaluates whether long-term β-blocker therapy after MI with preserved LVEF reduces all-cause death or new MI. Results may inform the role of β-blockers across MI subtypes.

Literature Evidence

Primary Indication: Posteroinferior Myocardial Infarction

PMID	Year	Type	Journal	Key Findings
3901170	1985	Crossover RCT	Rev Med Interne	Compared anti-ischaemic effects of atenolol (200 mg) vs diltiazem (240 mg) in 23 patients with residual ischaemia 4 weeks after posteroinferior or anterior MI. Used computerized exercise testing.

PMID	Year	Type	Journal	Key Findings
7257500	1981	Diagnostic study	Z Kardiol	Studied changes in regional myocardial perfusion with 201-Tl stress imaging in 14 patients before and after IV atenolol (5 mg). Evaluated perfusion in 6 LV segments including septal region.

PMID	Year	Type	Journal	Key Findings
31524	1978	Clinical study	Lille Med	Studied atenolol’s effects in chronic pulmonary patients with airway obstruction.
6673339	1983	Clinical study	Vutreshni Bolesti	Compared β-blockers in COPD patients with concomitant ischaemic heart disease over 14 days.
14520850	2003	Comparative study	Ter Arkh	Compared efficacy and safety of atenolol, metoprolol, and bisoprolol in isolated systolic hypertension with concomitant diabetes and/or COPD.
15881093	2005	Clinical study	Ter Arkh	Investigated respiratory disorders in IHD patients with COPD taking long-term atenolol.
28982831	2017	Observational	BMJ Open	Population-based retrospective cohort study on asthma-COPD overlap syndrome and cardiovascular disease associations.

Netherlands Market Information

The current evidence pack does not contain CBG-MEB regulatory data. However, atenolol is a well-established medicine widely available in the Netherlands under multiple marketing authorizations. It is registered in oral formulations (tablets 25 mg, 50 mg, 100 mg) and has been marketed in the EU for decades.

Data Gap: CBG-MEB license details were not included in this evidence pack. To complete this section, CBG-MEB authorization data should be retrieved from the Geneesmiddeleninformatiebank (GIB) at https://www.geneesmiddeleninformatiebank.nl.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for complete safety information.

Key Clinical Considerations for Posteroinferior MI:

AV Conduction: Posteroinferior MI frequently involves the AV node (supplied by the posterior descending artery). Atenolol may worsen AV block in these patients. ECG monitoring is essential before and during treatment.
Right Ventricular Involvement: Inferior MI may extend to the right ventricle. β-blockers can reduce preload-dependent cardiac output in RV infarction, potentially causing haemodynamic deterioration.
Bradycardia: Patients with inferior MI are prone to vagal-mediated bradycardia. Atenolol’s negative chronotropic effect may compound this risk.
Bronchospasm: Although β1-selective, atenolol’s selectivity diminishes at higher doses. Patients with concomitant reactive airway disease should be monitored.

All Predicted Indications Overview

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Key Concern
1	Posteroinferior myocardial infarction	99.87%	L4	Proceed with Guardrails	AV block risk; strong mechanistic rationale
2	Posterolateral myocardial infarction	99.87%	L5	Proceed with Guardrails	No direct evidence; mechanism applies
3	Malignant renovascular hypertension	99.85%	L4	Hold	β-blocker not first-line; doesn’t address root cause (RAS)
4	Malignant hypertensive renal disease	99.85%	L5	Hold	Insufficient potency for hypertensive emergency
5	Pulmonary hypertension (lung disease/hypoxia)	99.84%	L5	Hold	⛔ Contraindicated — may cause haemodynamic collapse
6	Pulmonary hypertension (multifactorial)	99.84%	L5	Hold	⛔ Contraindicated — β-blockers harmful in PH
7	Septal myocardial infarction	99.84%	L4	Proceed with Guardrails	Conduction bundle damage risk; mechanism applies
8	Braddock syndrome	99.80%	L5	Hold	No mechanistic link; rare genetic disorder
9	Chronic pulmonary heart disease	99.04%	L3	Research Question	Controversial; evidence inconsistent

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction for posteroinferior myocardial infarction is mechanistically sound — atenolol’s β1-selective blockade reduces myocardial oxygen demand and prevents reinfarction, and this mechanism is not dependent on infarct location. β-blockers are already standard-of-care for MI secondary prevention per ESC guidelines. However, the specific anatomical subtype (posteroinferior) carries additional risks (AV block, right ventricular involvement) that require heightened monitoring, and no dedicated clinical trials exist for this specific subtype.

Important safety flags across all predictions:

Predictions #5 and #6 (pulmonary hypertension) should be rejected — β-blockers are generally contraindicated in pulmonary hypertension and may cause life-threatening haemodynamic deterioration.
Prediction #8 (Braddock syndrome) has no mechanistic basis and should be disregarded.

To proceed, the following is needed:

Retrieve CBG-MEB authorization details and SmPC for atenolol products available in the Netherlands
Obtain detailed mechanism of action data from DrugBank (currently a data gap)
Conduct a focused literature review of β-blocker use stratified by MI anatomical subtype (inferior vs anterior vs lateral)
Monitor results of the REDUCE-SWEDEHEART trial (NCT03278509) for updated evidence on post-MI β-blocker benefit
Develop a safety monitoring protocol specifically addressing AV conduction and right ventricular function in posteroinferior MI patients
Consult SmPC warnings and contraindications (currently a data gap in this evidence pack)

Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Refer to the SmPC (Samenvatting van de Productkenmerken) for authoritative prescribing information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.